What is Altoida?
Altoida is pioneering a new standard in brain health through its Precision Neurology platform. Leveraging digital biomarkers (dBM), augmented reality (AR), and artificial intelligence (AI), the company has developed a validated device and platform rooted in over two decades of scientific research. Altoida's products are supported by peer-reviewed publications and multinational clinical trials, developed by a dedicated team of scientists, clinicians, and engineers. The company's approach aims to provide objective and scalable assessments for neurological conditions.
How much funding has Altoida raised?
Altoida has raised a total of $20.3M across 1 funding round:
Series A
$20.3M
Series A (2022): $20.3M with participation from Merck Ventures and White Cap
Key Investors in Altoida
Merck Ventures
M Ventures is the strategic venture capital arm of Merck, focusing on investments in innovative technologies and products that can significantly impact Merck's core business areas. They actively engage with portfolio companies to drive commercial success, with a strong emphasis on early-stage investments and company creation.
White Cap
White Cap is a leading distributor in the construction supply industry, providing a wide range of hardware, tools, and safety equipment to professional contractors. Their focus is on delivering high-quality products and comprehensive solutions to support the construction sector nationwide.
What's next for Altoida?
The recent major strategic investment signals Altoida's transition into a scaling phase, likely to accelerate product development, expand clinical validation, and broaden market penetration. This capital infusion is expected to bolster the company's efforts in establishing its Precision Neurology platform as a gold standard, potentially leading to new partnerships and wider adoption in the healthcare sector. The company's focus on digital biomarkers and AI positions it at the forefront of neurotechnology innovation.
See full Altoida company page
